Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Time to see the light.
Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis.
Immune cell trafficking from the brain maintains CNS immune tolerance.
Fampridine – Benefit assessment according to § 35a Social Code Book V
Neuropsychological Aspects of Childhood Multiple Sclerosis: An Overview.
Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis.
Targeting IRF4 in autoimmune diseases.
The attributable burden of panic disorder in the impairment of quality of life in a national survey in Italy.
Month of Birth Does Not Seem to Interfere with the Development of Multiple Sclerosis Later in Life in Brazilian Patients.
Santhera Receives European Marketing Authorization for Raxone® in Leber's Hereditary Optic Neuropathy (LHON)
Microglia Induce Neurotoxic IL-17+ γδ T Cells Dependent on TLR2, TLR4, and TLR9 Activation.
Kappa free light chains: diagnostic and prognostic relevance in MS and CIS.
No Association Between Conventional Brain MR Imaging and Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis.
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
The use of aminopyridines in neurological disorders.
Inflammatory Response and Chemokine Expression in the White Matter Corpus Callosum and Gray Matter Cortex Region During Cuprizone-Induced Demyelination.
Capture-Recapture as a Potentially Useful Procedure for Assessing Prevalence of Multiple Sclerosis: Methodologic Exercise Using Portuguese Data.
Association between multiple sclerosis and chronic periodontitis: a population-based pilot study.
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.
Role of the Programmed Death-1 (PD-1) pathway in regulation of Theiler's murine encephalomyelitis virus-induced demyelinating disease.
Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination.
Biomarkers in multiple sclerosis.
Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders.
The role of microbiome in central nervous system disorders.
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Pages
« first
‹ previous
…
136
137
138
139
140
141
142
143
144
…
next ›
last »